Timber Pharmaceutical News Today

LEO Pharma has acquired Timber Pharmaceuticals, in a deal that will add an ‘attractive’ late stage asset to its pipeline in medical dermatology, the company said.

Relmada Therapeutics (NASDAQ:RLMD – Get Free Report) and Timber Pharmaceuticals (NYSE:TMBR – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Insider & Institutional Ownership 59.1% of Relmada […]

Seres Therapeutics (NASDAQ:MCRB – Get Rating) and Timber Pharmaceuticals (NYSE:TMBR – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations. Analyst Ratings This is a breakdown of current ratings […]

Timber Pharmaceuticals, Inc. (NYSE:TMBR – Get Rating) – Equities research analysts at HC Wainwright raised their Q1 2023 earnings estimates for shares of Timber Pharmaceuticals in a note issued to investors on Monday, April 10th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($1.17) per share for the quarter, […]

Timber Pharmaceuticals (NYSE:TMBR – Get Rating) is one of 942 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Timber Pharmaceuticals to related businesses based on the strength of its risk, dividends, analyst recommendations, profitability, valuation, earnings and institutional ownership. Analyst Recommendations This is a breakdown […]

Timber Pharmaceuticals (NYSE:TMBR – Get Rating) is one of 942 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Timber Pharmaceuticals to related businesses based on the strength of its profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation. Analyst Recommendations This is a breakdown […]